Tarsus Pharmaceuticals, Inc. TARS 深 沪
等待开盘 05-21 09:30:00 美东时间
64.79
+3.500
+5.71%
华盛通- 最 高64.91
- 今 开61.38
- 成交量 122.92万股
- 最 低 61.38
- 昨 收 61.29
- 总市值 27.88亿
- 52周最高 85.25
- 市盈率 静 --
- 换手率 2.86%
- 52周最低 38.51
- 委 比 -75.88%
- 总股本 4302.40万
- 历史最高 85.25
- 量 比 1.63
- 振 幅 5.76%
- 历史最低 10.80
- 每 手 1
- 风险率 13.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tarsus Pharmaceuticals Collaborates With John Cena Over Eyelid Disease Demodex Blepharitis
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but often overlooked eyelid disease caused by microscopic mites that live
05-14 20:41
财报速睇 | Tarsus Pharmaceuticals, Inc. 2026财年Q1营收1.62亿美元，同比增长106.9%；归母净利润亏损0.07亿美元，同比亏损缩窄72.3%
华盛资讯5月7日讯，Tarsus Pharmaceuticals, Inc.公布2026财年Q1业绩，公司Q1营收1.62亿美元，同比增长106.9%，归母净利润亏损0.07亿美元，同比亏损缩窄72.3%。
05-07 05:22
财报速睇 | Tarsus Pharmaceuticals, Inc. 2026财年Q1营收1.62亿美元，同比增长107.7%；归母净利润亏损0.07亿美元，同比亏损缩窄72.0%
华盛资讯5月7日讯，Tarsus Pharmaceuticals, Inc.公布2026财年Q1业绩，公司Q1营收1.62亿美元，同比增长107.7%，归母净利润亏损0.07亿美元，同比亏损缩窄72.0%。
05-07 05:11
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and maintains $88 price target.
05-04 18:10
Tarsus Pharma Says First Participant Dosed In Phase 2 Clinical Trial Evaluating TP-05, Investigational Oral Therapy To Prevent Lyme Disease By Killing Lyme-Infected Ticks Before Disease Transmission Occurs
– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission –IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc.
03-31 20:33
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $90
Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $87 to $90.
02-25 22:24
Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
02-24 23:07
